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Introduction 
The background for the clinical development of 
FK506 was well documented by Starzl in the open-
ing remarks to a satellite symposium on FK506, 
held in Barcelona, Spain, in November 1989, of 
European Society of Organ Transplantation (1). 
Following the initial description of its discovery in 
1987 by Ochiai and coworkers, extensive in vitro 
studies demonstrated the effectiveness in suppress-
ing mixed lymphocyte cultures, presumably by in-
hibiting IL-2 synthesis following alloactivation (2, 
3). In vivo studies using a number of animal models 
have shown a marked ability to prevent rejection 
following various types of organ transplants (4-7). 
More interestingly, FK506 possesses the ability to 
reverse ongoing rejection in animal models (7-8). 
These properties served as the initiative to pursue 
clinical testing of FK506. 
The objective of this manuscript is to summarize 
the current experience of FK506 in human solid 
organ transplantation at the University of Pitts-
burgh. In addition to the efficacy of FK506, a 
delineation of the limitations, toxicities and bene-
fits, is also provided. 
Methods 
Study design 
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The trials in liver, kidney and heart transplantation 
were conducted at the University of Pittsburgh, 
Presbyterian University Hospital, Children's Hos-
pital of Pittsburgh and the Veterans Administra-
tion Medical Center, with the approval of the re-
spective Institutional Review Boards. Informed 
consent was obtained from patients or their ap-
pointed guardians. No attempt to chronologically 
report the results of the various studies is made, 
nor is this report to be taken as a representation of 
the total experience at the University of Pittsburgh. 
Patient profiles 
In the liver study, patients were treated with FK506 
as part of two studies, one being the rescue study 
in which 57 patients were entered for the diagnosis 
of acute rejection, while 116 patients were convert-
ed from cyclosporine to FK506 for chronic rejec-
tion. In the primary liver transplant group, 125 
patients were treated with FK506 and low-dose 
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steroids as the baseline immunosuppression follow-
ing liver transplantation. 
In the kidney study, patients were treated with 
FK506 as part of two studies, one being the rescue 
study in which 27 patients were entered for the 
diagnosis of rejection. In the primary kidney trans-
plant group, 202 kidney allografts received FK506 
and low-dose steroids as the baseline immunosup-
pression following kidney transplantation. 
In the heart study, patients were also divided 
into two studies. In one group, 42 patients were 
treated with FK506 as primary immunosuppres-
sion, while in the second group, 10 patients were 
converted to FK506 because of persistent rejection. 
Diagnostic evaluations 
For patients who were experiencing organ dysfunc-
tion, the final catagorization of dysfunction was 
based upon clinical, biochemical and/ or histo-
pathologic findings. For all patients, either as pri-
mary or as rescue therapy, cause(s) of organ dys-
function were carefully sought for, the workup 
being customized to the organ transplanted. Ultra-
sonic determination of vessel patency and radio-
graphic evaluation of the biliary or urinary system 
were used to rule out a technical or mechanical 
defect. Angiography was performed when indi-
cated. Appropriate viral cultures and stains were 
used to detect viral infections. 
Protocol biopsies were utilized in the evaluation 
of efficacy of FK506 therapy. All biopsies were 
blinded interpreted by a single experienced liver 
pathologist (AJD). Biopsy specimens were fixed in 
neutral buffered formalin and routinely stained 
with hematoxylin and eosin, trichrome and reticu-
lin stains. The criteria used for pathologic diagnosis 
have been clearly defined in previous reports (9, 
10). 
Timing and details of therapy 
Initiation of treatment with FK506 was done in 
the hospital and was given initially as a parenteral 
dose, followed by conversion to an oral dose. The 
initial parenteral dose of FKS06 was 0.07S to O.IS 
mg/kg, given intravenously over a period of 4 
hours, although a continuous infusion protocol 
was initiated in August, 1990. This was continued 
until the patient was able to ingest the oral form 
of FKS06. Generally, oral dosages of FK506 were 
given at 0.30 mg/kg/d, given in two divided doses. 
Dose adjustments of FKS06 were based upon 
monitoring of serum trough levels by ELISA (11) 
to achieve a 12-h trough level of 1.0 ng/ml, and 
also by adjustment according to clinical or bio-
chemical parameters. 
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Evaluation of response 
Periodic determinations of liver and kidney func-
tions, including total bilirubin (TBIL), serum glu-
tamic transaminases, SGOT and SGPT, alkaline 
phosphatase, blood urea nitrogen (BUN) and 
serum creatinine were performed. All values are 
expressed as the value plus/minus one standard 
deviation. Protocol biopsies were obtained after 
initiation of FK506 therapy. 
Results 
Liver transplantation 
Rescue therapy: In this population of 173 patients, 
in whom many were critically ill at the time of 
FKS06 conversion, a total of 14 deaths was en-
countered (8.1 %). The causes of death were numer-
ous, but the incidence of mortality was directly 
correlated with the medical condition of the patient 
at the time of FKS06 conversion. Sepsis was the 
cause of death in 4 patients. Three patients died of 
hemorrhagic complications. Three patients died of 
metastatic carcinoma following transplantation. In 
2 patients, retransplantation was not considered an 
option for the failing liver allograft. One patient 
was started on FKS06 with pathologic findings of 
late chronic rejection, and died of technical causes 
during an attempted retransplantation. In 1 death, 
no cause of death could be determined. This patient 
died at home and had been off of FK506 for 4 
months when she died. 
The biochemical response of the liver allografts 
to FK506 was analyzed by classifying patients 
either into acute or chronic rejection, depending 
upon the principal histopathologic findings. For 
the 57 patients who were treated for acute rejection, 
documented on liver biopsy or as judged by bio-
chemical and clinical parameters, the TBIL, SGOT 
and SGPT values, prior to FK506 were: 4.68 ± 5.91 
mg/ dl, 240 ± 431 IU 11, and 292 ± 383 IV / 1, respec-
tively. These values fell, by the 6th month, to: 
0.76± 1.41 mg/dl, 98± 163 lUll, and 90± 128 IV/ 
1, respectively. 
Patients with an entrance diagnosis of chronic 
rejection also had a beneficial response to FK506. 
For the 116 patients treated for this specific indi-
cation, the total bilirubin fell to normal values (pre-
FK506, S.07±8.16 mg/dl; 6 months, O.99±1.47 
mg/ dl) while the average transaminase values were 
still slightly elevated above normal values (pre-
FK506, SGOT/SGPT, 200±175 IV/1/275±223 
IV 11; 6 months, SGOT / SGPT, 44 ± 72 IV / 1/ 
101 ± 68 IV 11). 
In each case where histopathologic changes were 
predominant, the influence of FK506 on the initial 
findings of rejection or hepatitis could be evaluated 
in serial follow-up biopsies. Overall, 17% of biop-
sies with a diagnosis of rejection showed worsening 
of the pathology. 36'/', of liver biopsies showed no 
pathologic changes between the pre-FK506 biopsy 
and the 2-month followup biopsy: 47(% of the re-
maining biopsies showed improvement between the 
initial and followup biopsies. These changes were 
particularly impressive in patients whose pretreat-
ment biopsies contained bile duct lesions that gen-
erally progress to bile duct disappearance and graft 
loss, in spite of intensive immunosuppression. 
Primary therapy: Ten of the patients have died, 
leaving an actual survival of 92%. The follow up 
period was between 6 and 12 months. When com-
pared to 325 sequential liver transplants during the 
preceeding year prior to FKS06, the results are 
stastically significantly better in terms of patient 
and graft survival, in which the 6-month survival 
was 79%. This trend was seen in both the adult 
population (110 patients) and in the pediatric pop-
ulation (15 patients), although the numbers of 
pediatric patients in the trial were too small to 
achieve statistical significance. Of the 10 deaths, S 
were due to sepsis, I to heart failure, 1 to a cerebral 
vascular accident, 2 to non-reversible hepatic 
coma, and I to technical complications. 
During the followup period, 50% of all recipients 
were taken off steroids and were maintained on 
single-drug immunosuppression with FKS06. Yet 
52.8'/') of all patients were rejection-free during the 
entire period of study. The majority of rejection 
episodes were mild and were easily controlled with 
a single dose of bolus steroids (either methylpredni-
solone or hydrocortisone). Only 17.8% of the rejec-
tion episodes require further steroid treatment in 
the form of a steroid taper of additional steroid 
boluses. In addition. only 11.2% of the patients 
required. OKT3. 
The incidence of serious infections, in spite of 
the potency of FKS06, has not appeared to be 
alarming. Of note, is that the incidence of cytomeg-
alovirus infections did not appear to be increased, 
when compared to patients on cyclosporine. 
Randomized trial E~r FK506 versus CyA: A prelimi-
nary analysis of a randomized, prospective trial 
comparing FKS06 with CyA in primary liver trans-
plantation appears to verify the lower incidence of 
rejection and greater ease in treatment of rejection 
episodes, with less adverse effects. Eighty-one pa-
tients were randomized to either cyclosporine (n = 
41) or FK506 (n = 40), along with low-dose steroid 
therapy. The 6-month patient survival was 9S% for 
the FK506-treated group, while the corresponding 
value for the CyA-treated group was 890ft). The 
corresponding graft survival was 93% and 78%. 
FK506 
Two patients in the FK506-treated group and 6 
patients in the CyA-treated group were retrans-
planted. The total percentage of patients in the 
FKS06 group who were rejection-free during the 
entire length offollowup was 53.TYo, while that for 
CyA was 15.2%. The mean days to the first rejec-
tion was 21.5 d for the FK506-treated group, and 
was 9.9 d for the CyA-treated group. OKT3 was 
used in 30<Yo of CyA-treated patients, while only 
20% ofFKS06-treated patients received OKT3, for 
treatment of the original allograft: 67.5% of the 
CyA treated patients were converted to FK506, an 
average of 20 d after liver transplantation. 
Renal function in both groups of patients was 
assessed by the requirement for hemodialysis and 
the serum creatinine at monthly determinations. 
The comparative incidence for hemodialysis re-
quirement between the FKS06 and CyA groups 
was 10% and 21.6%, respectively. Longterm hemo-
dialysis (after 3 months post-transplant) was only 
required in I patient in each group. 
The incidence of opportunistic infections was 
essentially the same for both groups. Patients who 
were randomized to CyA had a 22.5% incidence of 
cytomegalovirus infections (CMV). This compared 
to 22.0% incidence for patients on FKS06. In the 
13 CyA patients who were not switched to FK506, 
the incidence of CMV was 23% (3/13), and only 1 
of the 3 patients received OKT3. In the FK506 
patients, 3 of the total 9 cases of CMV occurred 
in patients who had previously received OKT3. 
The severity of hypertension was assessed by the 
need for antihypertensive medications following 
transplantation. The incidence of hypertension in 
the overall CyA-randomized group was S2.9% ver-
sus 26.9% for the FKS06-treated group (p < 0.01), 
at 3 months post-transplant. The incidence of hy-
pertension in the 14 patients, who were on CyA at 
the 3-month post-transplant period, was 64.2'/') (9 
of 14 patients). 
Kidney transplantation 
Rescue therapy: A total of 27 patients were convert-
ed from cyc1osporine-based immunosuppression to 
FKS06-based immunosuppression for persistent 
kidney rejection. The median time to FKS06 rescue 
was 2 months (range 1 wk to 63 months). Three 
deaths were encountered (1 from cardiac arrhyth-
mia, I from hypertensive stroke and 1 from dis-
seminated Iymphoproliferative disease). Of the 27 
patients, 12 grafts were lost (including the 3 
deaths). Five had chronic rejection, 1 had severe 
CyA-related interstitial fibrosis. 1 was a primary 
non function with rejection, and the last suffered 
severe humoral rejection. 
There were IS successful rescue attempts. Acute 
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cellular rejection was the cause of kidney allograft 
dysfunction in 14/15 of these grafts. The overall 
serum creatinine prior to FK506 conversion in the 
successful switches was 5.1 ±4.4 mg/dl. The aver-
age creatinine after FK506 switch was 2.3 ± 1.2 
mg/ dl. There was a marked ability to utilize small 
doses of steroids, 3 were off prednisone, 3 were 
taking 5 mg/d, 2 were taking 7.5 mg/d, 5 were 
taking 10 mg/ d, 1 was taking 15 mg/ d, and 1 was 
taking 20 mg/ d. 
Primary therapy: FK506 was used from the outset 
with low doses of steroids to treat 202 primary 
kidney grafts. This was compared to a group of 
180 kidney allografts treated with CyA during the 
same period of time. Of the total 382 renal allo-
grafts transplanted, all but 37 were cadaveric renal 
allografts: 27% of the recipients were undergoing 
kidney retransplantation: 19% of the kidney allo-
grafts were pediatric en bloc kidney allografts. 
The actuarial patient survival following kidney 
transplantation was 96(10 for all patients; for the 
FK506 and CyA groups, the figures were 95% and 
97%, respectively. The corresponding l-yr graft 
survival was 83% and 85% for the FK506 and 
CyA groups, respectively. In the patients who were 
undergoing their first kidney transplant, the l-yr 
graft survival was 85% and 86%, while the l-yr 
graft survival in patients undergoing retransplan-
tation was 77% and 81%, for FK506 and CyA. The 
percentage of patients who experienced rejection 
was 57% for the FK506 group and 54% for the 
CyA group. The incidence of steroid-resistant re-
jection, which was reflected by the requirement for 
OKT3 use, was 21% for FK506-treated patients 
and 38% for CyA kidney patients. The mean serum 
creatinine and blood nitrogen was the same for 
both groups. 
Heart transplantation 
Rescue therapy: Ten patients were converted from 
cyclosporine to FK506 between 3 and 50 months 
post-transplant. The findings of persistent heart 
rejection defined by a > 2 + grading of the endo-
myocardial biopsy by the Billingham criteria (14), 
included mononuclear cell infiltration, arteritis and 
in some instances, interstitial fibrosis. All patients 
had failed conventional immunotherapy, including 
at least two courses of anti-lymphocyte prepara-
tions, and two courses of augmented steroids dur-
ing the preceding 6 months. The grading of endo-
myocardial biopsies, prior to conversion to FK506, 
was 2.70±0.48. Using the same criteria, the mean 
value of the followup biopsies after FK506 was 
graded at 0.70±0.67 (p<O.OI). The mean pred-
nisone dose prior to FK506 conversion was 14 mg/ 
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d, after FK506 conversion this fell to 5.5 mg/ d. 
Only 1 death occurred during the period of follow-
up in a patient with disseminated aspergillosis. 
Primary therapy: Forty-two patients received 
FK506 from the outset following heart transplan-
tation. Twenty-seven patients were on circulatory 
assist devices prior to heart transplantation. The 
mean followup was 40 d. Four patients have died, 
with an actual patient and graft survival of 93%. 
One patient with known pulmonary hypertension 
died on the 3rd post-transplant d from right heart 
failure. One patient, with preexisting lung disease 
and bronchietasis, died from pulmonary infection, 
while 2 other patients died sudden deaths, without 
a known cause of death. 
The rejection-free rate within the first 90 d was 
65%. Only 1 patient required OKT3. Heart func-
tion was excellent in all patients. The average left 
ventricular ejection fraction, determined by gated 
nuclear scans of echocardiography, was 70% (range 
58% to 75%). Hypertension, which was seen in 70% 
of CyA-treated heart transplant recipients, was 
only 15% in the heart transplant patients treated 
with FK506. 
Limitations 
Adverse reactions requiring treatment or adjust-
ment of FK506 doses can be catagorized into four 
primary areas. These are: 1) alterations in kidney 
function, 2) alterations in glucose metabolism, 3) 
neurotoxicity, and 4) susceptibility to infection or 
malignancy. Alterations in kidney function are 
manifested by electrolyte abnormalities and 
changes in glomerular filtration, as evidenced by 
changes in serum creatinine. Hyperkalemia is seen 
in 35% of patients following administration of 
FK506. Treatment of hyperkalemia is generally 
with potassium-binding resins and potassium-re-
stricted diets. Addition of a synthetic mineralocort-
icoid, Florinef, relieves the hyperkalemia by in-
creasing potassium excretion by the kidney. Dec-
rement in renal blood flow has been documented 
by nuclear medicine studies. The filtration fraction 
generally remains the same. Causes of altered renal 
function in transplant patients are multifactorial 
and include: peri operative hypotension, use of 
nephrotoxic antibiotics, and degree of preexisting 
renal dysfunction. The alteration in renal function 
seen in patients on FK506 is similar to that seen 
in patients on cyclosporine. These changes are re-
sponsive to reduction in doses of FK506. The inci-
dence of renal failure requiring chronic hemodialy-
sis is on the order of 4%, based on studies of 
liver transplant patients, although no patients have 
required maintenance hemodialysis following heart 
transplantation. The progression of chronic renal 
failure to dialysis requiring renal failure is not 
known. 
Alterations in glucose metabolism are the result 
of changes in peripheral sensitivity to insulin and/ 
or changes in the response of the islet cells to 
hyperglycemia. The incidence of new-onset dia-
betes, i.e., those patients requiring insulin, is ap-
proximately 15% in FK506 transplant patients. 
The incidence of new-onset diabetes in other im-
munosuppressive regimens, incorporating cyclo-
sporine, or azathioprine, is approximately 20%. 
The long-term consequence of insulin requirement 
in transplant patients, towards the development of 
diabetic complications, is not known. 
Rare but severe instances of neurotoxicity have 
been reported following FK506 administration. 
Expressive aphasia has been seen in 4 liver trans-
plant patients, although this has not been seen in 
any other types of FK506-treated patients. New-
onset seizures have also been reported in liver 
transplant patients, especially during the peri-
operative transplant period. The susceptibility of 
such patients to changes in serum electrolytes has 
been previously reported. New-onset seizures have 
not been reported in other patients treated with 
FK506. 
Post-transplant lymphoproliferative disease 
(PTLD) is an abnormality of lymphocyte prolifer-
ation in a setting of an immunosuppressed patient. 
The spectrum of PTLD can range from a benign 
lymphoid proliferation such as a mononucleosis 
syndrome to a frankly malignant lymphoid tumor. 
PTLD has been associated with all types of im-
munosuppressive therapy. The incidence of PTLD 
in the cyclosporine era is generally estimated be-
tween 2(Ytl and 4%. The median time following 
transplantation to the development of PTLD is 6 
months, while the majority of these tumors occur 
withlin 12 months following transplantation. 
A total of 16 patients have developed de novo 
PTLD lesions, while on FK506 therapy. Seven of 
these patients died, although PTLD was associated 
with death in only 5 deaths. The remaining 9 pa-
tients had relatively mild forms ofPTLD, 3 of these 
had a mononucleosis syndrome, with presentation 
of sore throat and tonsillar enlargement. Treatment 
with lower immunosuppression and intravenous 
acyclovir cured all of them. In the remaining 6 
patients, 3 required operative procedures (2 small 
bowel resections, 1 liver resection) which were di-
rectly related to PTLD, while the other 3 were 
treated by reduction of immunosuppression only. 
The incidence of de novo PTLD following initiation 
of FK506 therapy is 1.4%. All of the cases of PTLD 
occurred within the 1 st yr following initiation of 
FK506, with the median time from FK506 therapy 
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to onset of disease being 4 months. FK506 shows 
no evidence of any increase in the risk of develop-
ing or succumbing to PTLD, when compared to 
previously quoted figures on the incidence of 
PTLD, based on other immunosuppressive regi-
mens. No patients treated with FK506 for non-
transplanted indications have developed any malig-
nancies. 
Cytomegalovirus infections are considered the 
most common opportunistic infection in the trans-
plant patient. Several factors determine the severity 
and development of CMV infections. The serone-
gativity and use of intensive immunosuppression 
are considered major contributing factors. The in-
cidence of CMV infections in the FK506-treated 
transplant patients is 20%. This figure is similar to 
that seen in transplanted patients on cyclosporine. 
No patients treated with FK506 for non-transplant 
indications have developed CMV infections. 
Discussion 
Cyclosporine-based immunosuppression signifi-
cantly enhanced both patient and graft survival in 
all solid organ transplants, when compared to the 
era of azathioprine and steroids (12). The most 
common complicating factor has been the develop-
ment of rejection, occurring in over 60(1'0 of all 
cyclosporine-treated patients. In addition, the se-
quela of overimmunosuppression in attempts to 
treat rejection, such as use of excessive steroids, 
anti-lymphocyte preparations, are fraught with a 
high incidence of infectious complications. It 
stands to reason that a baseline immunosuppres-
sive agent which allows for less incidence of rejec-
tion, and easier treatment of rejection, would de-
crease both graft and patient loss. From the results 
of our preliminary studies presented here, the use 
of FK506 in liver transplantation has these advan-
tages. FK506 appears to not only decrease the 
absolute incidence of rejection episodes, and allows 
for marked reduction in steroid doses, but makes 
the treatment of rejection much simpler. 
The ability of a new immunosuppressive agent 
to be dose-adjustable for treatment of acute and 
chronic rejection would represent an important as-
set, which has only been ascribed to steroids in the 
past. FK506 can be used in this manner. In fact, 
the first response to a developing rejection is to 
increase the dose of baseline FK506. In rescue 
therapy, the marked ability of FK506 to reverse 
acute rejection in both kidney and heart rejection, 
and both acute and chronic rejection in liver trans-
plantation, has not been seen with any immuno-
suppressive agent in the past. While the mechanism 
by which FK506 is able to do this is not known, 
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it would appear that it would entail mechanisms 
other than simply inhibition of IL-2 synthesis. 
The mechanisms of action of FK506 and CyA 
are not clearly delineated. Both drugs bind to pro-
teins having a peptidyl-prolyl cis-trans isomerase 
activity (13). They also share some of the same 
side-effects, although they differ significantly in 
other important respects. The incidence of side-
effects of the two drugs is similar. Neurotoxicity is 
manifested by insomnia, mild tremors, headaches, 
photophobia and hyperesthesias. Gastrointestinal 
symptoms include diarrhea, anorexia, flatulence 
and gas bloating. One of the major benefits of 
FK506 appears to be a relative lack of some of 
the side-effects of cyclosporine. Some of these are 
cosmetic, such as hirsuitism and gingival hyper-
plasia, which has not been seen with FK506. Other 
more significant side-effects, such as hypertension, 
appear less in the FK506 patients than those on 
cyclosporine. Hypertension, which is seen in 
60-70% of all cyclosporine-treated patients, may 
result in complications such as hypertensive stroke, 
cardiomyopathy, and augment renal failure. The 
incidence of hypertension in FK506-treated pa-
tients appears to be at least 500;;) less. The ability 
to use less steroids in patients with FK506, when 
compared to cyclosporine, may result in less com-
plications ascribed to chronic steroid use, such as: 
osteoporosis, Cushinoid habitus, stunted growth, 
ulcerogenesis, diabetes. 
Prospective, randomized trials comparing 
FK506 therapy with cyclosporine-based immuno-
suppression are currently underway. These studies 
will help identify areas in which FK506 may be 
more advantageous, or more disadvantageous, 
than present-day immunosuppression. The initial 
preliminary results carried out in liver transplan-
tation, at this center are encouraging. The results at 
other centers will hopefully confirm these findings. 
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